For generations, Parkinson's disease has been understood as a tragedy of the brain — a slow erasure of movement and control. Now, researchers at University College London have traced the disease's origins to a far earlier chapter: the gut, where immune cells meant to protect the body may instead be escorting toxic proteins toward the mind. The discovery, published in Nature, suggests that the long silence between a patient's first digestive symptoms and their first tremor is not empty time, but a window — one in which the disease might, for the first time, be interrupted.
Gut immune cells identified as key pathway for Parkinson's spread to brain
Immune cells are not bystanders in Parkinson's disease
Mark
So the macrophages are supposed to be protective, but they're actually helping the disease spread?
Mimi
Not exactly. They're doing their job—consuming the toxic protein—but the protein damages them in the process. Once damaged, they send out signals that recruit other immune cells to the brain. It's like a security guard who gets poisoned while stopping a thief, and in his confusion, he opens the gate.
Mark
And this only happens in people with Parkinson's, or is it a normal immune response?
Mimi
That's the crucial question. The macrophages are responding, but in a dysfunctional way. In a healthy person, the response might be different. The researchers want to understand what goes wrong—why these cells malfunction in some people and not others.
Mark
If you reduce the macrophages, the disease doesn't spread as much. But aren't those cells important for fighting infection?
Mimi
Absolutely. That's why the real goal isn't to eliminate them, but to restore their function. You want them to handle the toxic protein correctly, not to get rid of them entirely. That's much harder, but it's the only sustainable approach.
Mark
How early could you actually catch this?
Mimi
The data suggests decades early. If someone has gut symptoms in their 40s or 50s, they might not develop movement symptoms until their 70s or 80s. A blood test could theoretically identify the immune dysfunction long before that window closes.
Mark
And then what? You can't cure it yet.
Mimi
Not yet. But you could intervene—manage the immune response, slow the spread, maybe prevent it entirely. The disease takes a long time to reach the brain. That's your opportunity.
O Pulso
- Gut macrophages — the body's own cellular defenders — are being hijacked by misfolded alpha-synuclein proteins, turning a protective mechanism into a disease highway to the brain.
- When researchers introduced toxic proteins into mouse intestines, T cells received distress signals from compromised macrophages and carried the disease directly into brain tissue.
- Depleting gut macrophages in mice before exposure dramatically reduced brain toxin accumulation and measurably improved motor function, proving the pathway can be disrupted.
- Up to 90% of Parkinson's patients suffered gut symptoms — often severe constipation — decades before any movement disorder appeared, revealing a vast, largely ignored early-warning window.
- The research team is now racing to develop blood tests that detect immune dysfunction before neurological damage begins, and to identify drug targets that could block the gut-to-brain transmission entirely.
For generations, Parkinson's disease has been understood as a tragedy of the brain — a slow erasure of movement and control. Now, researchers at University College London have traced the disease's origins to a far earlier chapter: the gut, where immune cells meant to protect the body may instead be escorting toxic proteins toward the mind. The discovery, published in Nature, suggests that the long silence between a patient's first digestive symptoms and their first tremor is not empty time, but a window — one in which the disease might, for the first time, be interrupted.
Scientists at University College London have identified how Parkinson's disease travels from the gut to the brain — a finding that could make it possible to stop the disease before its most devastating symptoms ever appear. At the center of the discovery is the macrophage, an immune cell that normally consumes harmful invaders. In Parkinson's patients, these gut macrophages engulf misfolded alpha-synuclein proteins — the toxic signature of the disease — but their internal disposal systems break down in the process. Critically, these compromised cells then signal T cells to travel from the gut into the brain, carrying the toxic protein with them.
The research team demonstrated the mechanism by introducing alpha-synuclein extracted from deceased Parkinson's patients into the intestines of mice, then tracking the cellular journey that followed. When they reduced the number of gut macrophages before exposure, far less toxic protein accumulated in the brain — and the mice's motor function improved. The implication is significant: these immune cells are not passive bystanders but active, if unwitting, agents of the disease's spread.
The timing of this discovery carries particular weight. Between half and nearly all people eventually diagnosed with Parkinson's experienced gut symptoms — often severe constipation — years or even decades before any movement problems emerged. This "body-first" progression, seen in roughly two-thirds of patients, means the disease spends years in the periphery before reaching the brain. That gap is a potential intervention window.
Study leaders Dr. Soyon Hong and Dr. Tim Bartels are now focused on translating the finding into clinical tools: blood tests capable of detecting early immune dysfunction, and drug targets that could interrupt the gut-to-brain pathway before neurological damage occurs. The research reframes Parkinson's not as a disease that originates in the brain, but as a systemic condition that begins elsewhere — and might, with early enough detection, be stopped before it ever arrives.
Scientists at University College London have identified the cellular mechanism by which Parkinson's disease travels from the gut to the brain—a discovery that opens the possibility of stopping the disease before it causes the tremors and movement problems that define it. The finding centers on a type of immune cell called a macrophage, which normally protects the body by consuming harmful invaders. In Parkinson's patients, these gut macrophages appear to be doing exactly that—but in the process, they're inadvertently ferrying toxic proteins toward the brain.
For decades, researchers have suspected that Parkinson's begins not in the brain but in the digestive system. The clue lies in anatomy: the vagus nerve, which connects the gut directly to the brain, is one of the first regions affected in the disease. Yet the mechanism remained mysterious. How does a disease that starts in the intestines reach the brain? The new study, published in Nature and led by researchers at the UK Dementia Research Institute, provides an answer.
The team took misfolded alpha-synuclein—the toxic protein at the heart of Parkinson's—extracted from the brains of deceased patients and introduced small amounts into the small intestines of mice. They then tracked what happened. The gut macrophages, acting as cellular scavengers, engulfed the protein. But in doing so, their internal waste-disposal systems became dysfunctional. More critically, these compromised macrophages sent signals to T cells, immune cells that normally help fight infection. These T cells, now "instructed" by the damaged macrophages, traveled from the gut into the brain, carrying the toxic protein with them.
The implications became clear when researchers depleted the number of gut macrophages before introducing the toxic protein. Mice without sufficient macrophages showed significantly less alpha-synuclein accumulation in their brains compared to normal mice—and their motor symptoms improved. The finding suggests a therapeutic strategy: prevent these immune cells from making the journey, or restore their function so they handle the toxic protein correctly.
The timing of this discovery matters enormously. Between 50 and 90 percent of people eventually diagnosed with Parkinson's experienced gut symptoms—often severe constipation—decades before any movement problems appeared. About two-thirds of Parkinson's patients fall into this "body-first" category, where disease begins in the periphery before reaching the brain. If the disease takes years or decades to travel from gut to brain, there is a window for intervention. A simple blood test detecting early markers of immune dysfunction could identify at-risk people long before neurological damage occurs.
Dr. Soyon Hong, one of the study's leaders, emphasized that these macrophages are not passive bystanders but active participants in disease progression—albeit in a malfunctioning way. The goal now is to understand how to restore their proper function, so they respond correctly to the toxic protein rather than facilitating its spread. Dr. Tim Bartels, the study's co-lead author, pointed toward the practical endpoint: early detection through blood screening, followed by intervention before the brain is affected. For a disease that has no cure and progresses relentlessly once symptoms appear, the ability to catch it in its earliest stages—in the gut, years before tremors begin—could fundamentally change outcomes.
The research team's next steps involve mapping how the immune system's dysfunction contributes to neurodegeneration, identifying drug targets that could interrupt the gut-to-brain pathway, and developing those blood-based diagnostics. The work represents a shift in how scientists think about Parkinson's: not as a brain disease that happens to start there, but as a systemic disease that begins elsewhere and can potentially be stopped before it arrives.
Citações Notáveis
These gut macrophages are responding, albeit in a dysfunctional way. This presents an opportunity to think about how we can boost the function of the immune system and these cells, so that they respond in the correct manner and help to slow or stop the spread of disease.— Dr. Soyon Hong, Co-lead Author, UK Dementia Research Institute at UCL
Understanding how Parkinson's begins in the body could allow us to develop simple blood tests to screen for it, enabling diagnosis long before damage to the brain starts.— Dr. Tim Bartels, Co-lead Author, UK Dementia Research Institute at UCL
Quer a matéria completa?
Leia o original em News-Medical.net ↗
Education